Skip to main content
Premium Trial:

Request an Annual Quote

ProPath to Use CombiMatrix's Chromosomal Microarray Testing for Miscarriage Analysis

NEW YORK (GenomEWeb News) - CombiMatrix said today that it will provide chromosomal microarray analysis-based testing for miscarriage analysis for ProPath, a pathology services provider.

The agreement enables ProPath to add a new product to its suite of women's health diagnostics, one that "can play a significant role in a comprehensive miscarriage analysis," according to Kenneth Youens, ProPath's women's health director. He added that "the accuracy, clinical utility and quick turnaround times of CMA testing makes it a superior first tier testing option."

CombiMatrix President and CEO, Mark McDonough noted that "CMA is especially important in the case of stillbirths or miscarriages because it can provide parents valuable information about future pregnancies."

The financial details of the partnership were not disclosed.